Primary Central Nervous System Lymphoma

A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma

Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma

A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL

Pembrolizumab, Ibrutinib and Rituximab in PCNSL

Methotrexate Early Toxicity Monitoring

Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma

Q702 for the Treatment of Patients With Hematologic Malignancies

A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL

New-diagnosed PCNSL Treated With Methotrexate (MTX) and Orelabrutinib-based Regimen

[18F]-Fludarabine PET/MRI in Primary Central Nervous System Lymphoma

Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL

Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response

Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL

Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104)

Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma